Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Spironolactone and doxazosin treatment in patients with resistant hypertension.

Rodilla E, Costa JA, Pérez-Lahiguera F, Baldó E, González C, Pascual JM.

Rev Esp Cardiol. 2009 Feb;62(2):158-66. English, Spanish.

3.

Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?

Verdalles U, García de Vinuesa S, Goicoechea M, Macías N, Santos A, Perez de Jose A, Verde E, Yuste C, Luño J.

Nephrology (Carlton). 2015 Aug;20(8):567-71. doi: 10.1111/nep.12475.

PMID:
25818266
4.

The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension.

Vaclavik J, Sedlak R, Jarkovsky J, Kocianova E, Taborsky M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013 Mar;157(1):50-5. doi: 10.5507/bp.2012.078. Epub 2012 Oct 31.

5.

[Spironolactone in patients with resistant hypertension].

Rodilla E, Costa JA, Pérez-Lahiguera F, González C, Pascual JM.

Med Clin (Barc). 2008 Oct 4;131(11):406-11. Spanish.

PMID:
18928720
6.

Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.

Ohta Y, Tsuchihashi T, Onaka U, Eto K, Ueno M.

Hypertens Res. 2007 Apr;30(4):301-6.

PMID:
17541208
7.

Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.

Václavík J, Sedlák R, Plachy M, Navrátil K, Plásek J, Jarkovsky J, Václavík T, Husár R, Kociánová E, Táborsky M.

Hypertension. 2011 Jun;57(6):1069-75. doi: 10.1161/HYPERTENSIONAHA.111.169961. Epub 2011 May 2. Erratum in: Hypertension. 2015 Feb;65(2):e7.

PMID:
21536989
8.

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society's PATHWAY Studies Group.

Lancet. 2015 Nov 21;386(10008):2059-2068. doi: 10.1016/S0140-6736(15)00257-3. Epub 2015 Sep 20.

9.

Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.

Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK, Caulfield MJ, Padmanabhan S, Mackenzie IS, Salsbury J, Brown MJ; British Hypertension Society programme of Prevention And Treatment of Hypertension With Algorithm based Therapy (PATHWAY) Study Group.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):464-475. doi: 10.1016/S2213-8587(18)30071-8. Epub 2018 Apr 11. Erratum in: Lancet Diabetes Endocrinol. 2018 Aug;6(8):e16.

10.

Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.

Pessina AC, Ciccariello L, Perrone F, Stoico V, Gussoni G, Scotti A, Muggeo M.

Nutr Metab Cardiovasc Dis. 2006 Mar;16(2):137-47. Epub 2005 Oct 20.

PMID:
16487914
11.

Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial.

Oliveras A, Armario P, Clarà A, Sans-Atxer L, Vázquez S, Pascual J, De la Sierra A.

J Hypertens. 2016 Sep;34(9):1863-71. doi: 10.1097/HJH.0000000000001025.

12.
13.

A Systematic Review of Add-on Pharmacologic Therapy in the Treatment of Resistant Hypertension.

Tataru AP, Barry AR.

Am J Cardiovasc Drugs. 2017 Aug;17(4):311-318. doi: 10.1007/s40256-017-0224-5. Review.

PMID:
28349274
14.

Addition of spironolactone in patients with resistant hypertension: A meta-analysis of randomized controlled trials.

Liu L, Xu B, Ju Y.

Clin Exp Hypertens. 2017;39(3):257-263. doi: 10.1080/10641963.2016.1246564. Review.

PMID:
28448185
15.

Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: insights from the aspirant trial.

Vaclavik J, Sedlak R, Jarkovsky J, Kocianova E, Taborsky M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014 Sep;158(3):384-90. doi: 10.5507/bp.2012.105. Epub 2012 Dec 7.

16.

A meta-analysis of add-on use of spironolactone in patients with resistant hypertension.

Zhao D, Liu H, Dong P, Zhao J.

Int J Cardiol. 2017 Apr 15;233:113-117. doi: 10.1016/j.ijcard.2016.12.158. Epub 2016 Dec 29. Review.

PMID:
28089457
17.

Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment).

Krieger EM, Drager LF, Giorgi DMA, Pereira AC, Barreto-Filho JAS, Nogueira AR, Mill JG, Lotufo PA, Amodeo C, Batista MC, Bodanese LC, Carvalho ACC, Castro I, Chaves H, Costa EAS, Feitosa GS, Franco RJS, Fuchs FD, Guimarães AC, Jardim PC, Machado CA, Magalhães ME, Mion D Jr, Nascimento RM, Nobre F, Nóbrega AC, Ribeiro ALP, Rodrigues-Sobrinho CR, Sanjuliani AF, Teixeira MDCB, Krieger JE; ReHOT Investigators.

Hypertension. 2018 Apr;71(4):681-690. doi: 10.1161/HYPERTENSIONAHA.117.10662. Epub 2018 Feb 20.

PMID:
29463627
19.

Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension.

Williams B, MacDonald TM, Caulfield M, Cruickshank JK, McInnes G, Sever P, Webb DJ, Salsbury J, Morant S, Ford I, Brown MJ.

BMJ Open. 2015 Aug 7;5(8):e008951. doi: 10.1136/bmjopen-2015-008951.

20.

Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.

Ghazi L, Dudenbostel T, Lin CP, Oparil S, Calhoun DA.

J Hypertens. 2016 May;34(5):1005-10. doi: 10.1097/HJH.0000000000000870.

Supplemental Content

Support Center